Jubilant Pharmova Ltd
NSE:JUBLPHARMA

Watchlist Manager
Jubilant Pharmova Ltd Logo
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Watchlist
Price: 1 097.4 INR 2.75% Market Closed
Market Cap: 174.8B INR
Have any thoughts about
Jubilant Pharmova Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

28.9
Current
20
Median
16.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
28.9
=
Enterprise Value
188.4B INR
/
EBIT
6.5B INR
All Countries
Close
EBIT Growth EV/EBIT to Growth
IN
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Average EV/EBIT: 1 813
28.9
135%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
23.9
2-Years Forward
EV/EBIT
18.9
3-Years Forward
EV/EBIT
15.3

See Also

Discover More